PURCHASE, N.Y. Nutrition 21 on Tuesday reported that results of a randomized, double-blind, placebo-controlled clinical study published online in Diabetes Technology & Therapeutics found that Nutrition 21's Chromax chromium picolinate significantly reduced hunger levels by 24 percent, food intake by 25 percent, and also reduced cravings for high-fat foods in adult non-diabetic overweight women.
“Study subjects were allowed to eat any type and amount of food throughout the study,” stated Dr. Steve Anton, investigator and lead author of the study. “The participants who received chromium picolinate reduced their caloric intake by an average of 365 calories per day between their baseline and final (week 8) visit.”
“These results show that Chromax chromium picolinate can be useful for overweight individuals desiring to reduce their food intake,” noted James Komorowski, Nutrition 21 vice president, technical services and scientific affairs. “The published study also provides clinical substantiation for reduced hunger and reduced cravings claims for food and supplement manufacturing companies that use Chromax in their formulations.”
The study was conducted by researchers at the Pennington Biomedical Research Center, the largest academically based nutrition research center in the world.
The randomized, double-blind, placebo-controlled, 8-week study, entitled “Effects of Chromium Picolinate on Food Intake and Satiety,” was published online in Diabetes Technology & Therapeutics and is scheduled to be released in the October 2008 print issue of the journal.
The study population comprised 42 overweight adult women who reported craving carbohydrates. Subjects were given either Chromax chromium picolinate capsules (containing 1,000 micrograms chromium) or matching placebo capsules for 8 weeks. Food intake was directly measured at the research center’s eating laboratory at baseline, after 1 week and again after 8 weeks.